Objective To assess the prevalence of potential drug–drug interactions (DDIs) in bone marrow transplantation (BMT) patients at the time of pre-infusion (day −1), to describe the potential DDIs and assess their frequency and severity. Setting The study was developed in a tertiary care hospital in São Paulo, Brazil. Method Cross-sectional study based on examining the medical prescriptions from the pre-infusion day (day −1) of 70 BMT patients. Potential DDIs were analyzed using Drug-Reax® and categorized according to levels of severity, evidence, and onset (rapid and delayed). Only interactions of major or moderate severity were included in the potential DDI analysis. Main outcome measure: Prevalence of potential DDIs in patients during the preinfusion phase of BMT. Results Data were analysed for 70 BMT patients. The median age was 36.5 years; 52.9% (37) of the patients were male, and 65.7% (46) were undergoing autologous BMT. The patients received a median of 8 drugs each. Up to 128 potential DDIs were detected, 60.0% (42) of patients had at least 1 potential DDI and 21.4% (15) were exposed to at least 1 major potential DDI. The most commonly involved drugs were cyclosporine (9, 28.1%), phenytoin (8, 25%) and fluconazole (5, 15.6%). Most potential DDIs had moderate severity (110, 85.9%), a pharmacokinetic mechanism (67, 52.3%), and were classified as delayed onset (106, 82.8%). For major interactions, fluconazole + sulfamethoxazole/trimethoprim, diazepam + fentanyl, fluconazole + levofloxacin and fentanyl + fluconazole were the most frequent. Conclusions The prevalence of potential DDIs during the conditioning period of BMT was high as a consequence of the therapeutic complexity of the procedure. Most potential DDIs identified in the study may result in clinically relevant consequences as they could lead to nephrotoxicity, cardiotoxicity, and other undesirable adverse effects. Careful monitoring of clinical and laboratory parameters is essential to ensure a successful BMT and to avoid adverse drug events related to DDI.
Bone marrow transplantation Brazil Drug–drug interactions Drug utilization Medication safety Pharmacotherapy
This is a preview of subscription content, log in to check access.
Van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011. (ahead of print). doi:10.1093/annonc/mdq761.
Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600.PubMedCrossRefGoogle Scholar
Mihara A, Mori T, Aisa Y, Yamazaki R, Iketani O, Tanigawara Y, Ikeda Y, Okamoto S. Greater impact of oral fluconazole on drug interaction with intravenous calcineurin inhibitors as compared with intravenous fluconazole. Eur J Clin Pharmacol. 2008;64:89–91.PubMedCrossRefGoogle Scholar
Secoli SR, Figueras A, Lebrão ML, Lima FD, Santos JL. Risk of potential drug–drug interactions among Brazilian elderly: a population-based, cross-sectional study. Drugs Aging. 2010;27:759–70.PubMedCrossRefGoogle Scholar
Nagamura F, Takahashi T, Takeuchi M, Iseki T, Ooi J, Tomonari A, Uchimaru K, Takahashi S, Tojo A, Tani K, Asano S. Effect of cyclophosphamide on serum cyclosporine levels at the conditioning of hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;32:1051–8.PubMedCrossRefGoogle Scholar
Egger SS, Meier S, Leu C, Christen S, Gratwohl A, Krähenbühl S, Haschke M. Drug interactions and adverse events associated with antimycotic drugs used for invasive aspergillosis in hematopoietic SCT. Bone Marrow Transplant. 2010;45:1197–203.PubMedCrossRefGoogle Scholar
Reis AMM, Cassiani SHB. Evaluation of three brands of drug interaction software for use in intensive care units. Pharm World Sci. 2010;32(6):822–828. doi:10.1007/s11096-010-9445-2.
World Health Organization. Collaborating Center for Drug Statistics Methodology. ATC/DDD Index 2011. Available from URL: http://www.whocc.no/atcddd/index. Accessed 04 Aug 2011.
Riechelmann RP, Zimmermann C, Chin SN, Wang L, O’Carroll A, Zarinehbaf S, Krzyzanowska MK. Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symp Manag. 2008;35:535–43.CrossRefGoogle Scholar
Leather HL. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant. 2004;33:137–52.PubMedCrossRefGoogle Scholar
Freeman DL, Laupacis A, Keown PA, Stiller CR, Carruthers SG. Evaluation of cyclosporine—phenytoin interaction with observations on cyclosporine metabolites. Br J Clin Pharmacol. 1984;18(6):887–93.PubMedGoogle Scholar
Keown PA, Laupacis A, Carruthers G, Stawecki M, Koegler J, McKenzie FN, Wall W, Stiller CR. Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation. 1984;38(3):304–6.PubMedGoogle Scholar
Ng TM, Bell AM, Hong C, Hara JM, Touchette DR, Danskey KN, Lindsay TT, Puumala SE. Pharmacists monitoring of QTc interval—prolonging medications in critically ill medical patients: a pilot study. Ann Pharmacother. 2008;42:475–82.PubMedCrossRefGoogle Scholar
Crouch MA, Limon L, Cassano AT. Clinical relevance and management of drug related QT interval prolongation. Pharmacotherapy. 2003;23:881–908.PubMedCrossRefGoogle Scholar
Gandhi PJ, Menezes PA, Vu HT, Rivera AL, Ramaswamy K. Fluconazol and levofloxacin—induced torsades de pointes in an intensive care unit patient. Am J Health Syst Pharm. 2003;60:2479–83.PubMedGoogle Scholar
Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730–44.PubMedCrossRefGoogle Scholar
Yu DT, Peterson JF, Seger DL, Gerth WC, Bates DW. Frequency of potential azole drug–drug interactions and consequences of potential fluconazole drug interactions. Pharmacoepidemiol Drug Saf. 2005;14:755–67.PubMedCrossRefGoogle Scholar
Lopez-Gil JA. Fluconazole-cyclosporine interaction: a dose-dependent effect? Ann Pharmacother. 1993;27:427–30.PubMedGoogle Scholar
Egger SS, Drewe J, Shlienger RG. Potential drug–drug interactions in the mediation of medical patient at hospital discharge. Eur J Clin Pharmacol. 2003;58:773–8.PubMedGoogle Scholar
Delafuente JC. Understanding and preventing drug–drug interactions in elderly patients. Critic Rev Oncol Hematol. 2003;48:133–43.CrossRefGoogle Scholar
Zwart-van Rijkom J, Uijtendaal E, Ten Berg M, Van Solinge W, Egberts A. Frequency and nature of drug–drug interactions in a Dutch university hospital. Br J Clin Pharmacol. 2010;68(2):187–93.CrossRefGoogle Scholar
Leone R, Magro L, Moretti U, Cutroneo P, Moschini M, Motola D, Tuccori M, Conforti A. Identifying adverse drug reactions associated with drug–drug interactions: data mining of a spontaneous reporting database in Italy. Drug Saf. 2010;33(8):667–75.PubMedCrossRefGoogle Scholar
Cruciol-Souza JM, Thomson JC. A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics. 2006;61(6):515–20.PubMedCrossRefGoogle Scholar
Vonbach P, Dubied A, Krähenbühl S, Beer JH. Recognition and management of potential drug–drug interactions in patient on internal medicine wards. Eur J Clin Pharmacol. 2007;63:1075–83.PubMedCrossRefGoogle Scholar